MedTrace Logo

A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis

NCT05314517 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2025-09-12

Study results available
· View outcomes & findings →

Summary

This is a randomized, double-blind, placebo-controlled study with an open-label extension (OLE).

Conditions

  • Sarcoidosis, Pulmonary

Interventions

DRUG

Namilumab

Namilumab administered subcutaneously

DRUG

Placebo

Placebo administered subcutaneously to match namilumab dosing

Sponsors & Collaborators

  • Kinevant Sciences GmbH

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-31
Primary Completion
2024-10-16
Completion
2025-04-09
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • France
  • Germany
  • Netherlands
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05314517 on ClinicalTrials.gov